In patients with HER2 + breast cancer, elevated levels of anti-HER2 CD4 + T-bet + IFN-γ + Th1 cells correlate with pathologic responses following neoadjuvant trastuzumab and chemotherapy, and they are associated with a reduced risk of recurrence and improved prognosis [16]. Here, CD4 is linked to breast carcinoma.